J&J to buy Intra-Cellular Therapies for $14.6 billion
1. Johnson & Johnson to acquire Intra-Cellular Therapies for $14.6 billion. 2. This acquisition enhances J&J's position in neurological disorder treatments.
FAQ
Why Bullish?
The J&J acquisition may boost ITCI's market perception and valuation as a target. Previous acquisitions in biotech often led to price appreciation for the acquired firms.
How important is it?
The acquisition reflects confidence in ITCI's drug portfolio, potentially making it more valuable.
Why Short Term?
Initial investor sentiment may increase ITCI's price due to the acquisition news. Short-term reactions to M&A are typically more pronounced.